Zydus Lifesciences Limited · NSE:ZYDUSLIFE
Zydus Lifesciences — Q2 FY22 Earnings Presentation
16 slides from Zydus Lifesciences's earnings presentation, Oct 29, 2021
Slide 1: Investor Presentation Q2FY22
Investor Presentation Q2FY22 29th October, 2021
Slide 2: Disclaimer and Safe Harbor Statement
Disclaimer and Safe Harbor Statement • THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF CADILA HEALTHCARE LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE “COMPANY”). The material that follows is a Presentation of general
Slide 3: Consolidated Financial Highlights Q2 FY22
Consolidated Financial Highlights Q2 FY22 Consolidated Revenue from operations at INR 3,785 Crores, up 3% Y-o-Y and ….. Revenue …..down 6% Q-o-Q. INR Crores Y-o-Y Q-o-Q Consolidated EBIDTA at INR 861 Crores up 6% Y-o-Y and down 8% Q-o-Q. ….. 3,785 3% -6% …..EBIDTA margin for Q2’22 is 22.7%, agai
Slide 4: Consolidated Financial Performance Q2 FY22
Consolidated Financial Performance Q2 FY22 Q-o-Q Y-o-Y Particulars (INR Crore) Q2 FY22 Q1 FY22 Q2 FY21 H1 FY22 H1 FY21 Growth Growth Growth Revenue from operations 3,785 4,025 -6% 3,659 3% 7,810 7,174 9% 1. On a Y-o-Y basis, growth in revenue Other income 53 32 69% 28 94% 85 50 70% was driven by str
Slide 5: Margin Trends
Margin Trends • PBT and PAT Margins are excluding exceptional and one off items • ^ 1.1% represents one time inventory provision for Covid related products 5
Slide 6: Business wise Sales Q2 FY22
Business wise Sales Q2 FY22 INR Crores Market, Sales Value Q2 21-22 % share in consolidated sales ▲% Growth 6
Slide 7: Business wise Sales H1 FY22
Business wise Sales H1 FY22 INR Crores Market, Sales Value H1 21-22 % share in consolidated sales ▲% Growth 7
Slide 8: India Geography: Human health formulations business
India Geography: Human health formulations business INR Crores Highlights Excluding the institutional sales of COVID products, the business grew by 17% Y-o-Y which was driven by strong volume growth and new products launched during last few quarters. Gained market share in anti-diabetic and card
Slide 9: India Geography: Consumer Wellness
India Geography : Consumer Wellness INR Crores Highlights Complan brand re-launched after a gap of 4 years with enhanced proposition, improved chocolate taste, new packaging along with new campaign to promote the brand. The brand witnessed double digit growth. EverYuth brand continued to grow in
Slide 10: US Formulations Business
US Formulations Business INR Crores Highlights The business saw a sequential growth in revenues despite heightened competition and tough pricing scenario. Overall volumes grew despite the reduction in volumes of Mesalamine products as there was a gain in volume of other existing products and new
Slide 11: Emerging Markets
Emerging Markets INR Crores Highlights Demand led base business growth regained momentum in key markets Regulatory organizations in most of the countries operated at sub- optimal level with focus being COVID management which resulted in new launches being pushed to next calendar year. Y-o-Y ▲48%
Slide 12: Innovation - Covid19 updates
Innovation - Covid19 updates ZyCov-D received EUA from DCGI; 1st Plasmid DNA vaccine for human use approved anywhere in the world. ZyCov-D approval was received for the adolescents in 12-18 years age group as well besides the adult population, making it the first vaccine for the adolescents in 1
Slide 13: Innovation - other updates
Innovation - other updates NCE: Saroglitazar Magnesium: Biologics: Initiated enrolment of patients for EVIDENCES-X, a global pivotal Submitted an application to DCGI to initiate Phase III clinical trials Phase II(b) CTs to evaluate the efficacy and safety in subjects with for one monoclonal anti
Slide 14: Thank you
Thank you 14
Slide 15: Glossary
Glossary • Revenue from operations represents Sales and other operating revenues. • Net debt: It is defined as the sum of long-term borrowings, short-term borrowings, minus cash and cash equivalents, current investments, and other bank balances. • EBIDTA: Earnings before interest, depreciation, taxa
Slide 16: Details of other incomes and foreign exchange fluctuations
Details of other incomes and foreign exchange fluctuations Other Operating Income Y-o-Y YTD YTD Y-o-Y Particulars (INR Crore) Q2 21-22 Q2 20-21 Growth 21-22 20-21 Growth Export Incentive 10 47 -77.7% 20 96 -79.5% Royalty Income 3 0 8302.6% 7 0 6591.9% Exchange Rate Fluctuations 26 -13 307.3% 79 - Pr